Related references
Note: Only part of the references are listed.Optimization of pyrazole-containing 1,2,4-triazolo-[3,4-b]thiadiazines, a new class of STAT3 pathway inhibitors
Matthew G. LaPorte et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2016)
The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations
Jessica L. Geiger et al.
ORAL ONCOLOGY (2016)
HCS Campaign to Identify Selective Inhibitors of IL-6-Induced STAT3 Pathway Activation in Head and Neck Cancer Cell Lines
Paul A. Johnston et al.
ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES (2015)
Cancer Statistics, 2015
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
Current Treatment Options for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Assuntina G. Sacco et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
EGFR inhibition for recurrent or metastatic HNSCC
Athanassios Argiris
LANCET ONCOLOGY (2015)
High-Content pSTAT3/1 Imaging Assays to Screen for Selective Inhibitors of STAT3 Pathway Activation in Head and Neck Cancer Cell Lines
Paul A. Johnston et al.
ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES (2014)
In Vitro Assay of Six UDP-Glucuronosyltransferase Isoforms in Human Liver Microsomes, Using Cocktails of Probe Substrates and Liquid Chromatography-Tandem Mass Spectrometry
Kyung-Ah Seo et al.
DRUG METABOLISM AND DISPOSITION (2014)
Quantification of Human Uridine-Diphosphate Glucuronosyl Transferase 1A Isoforms in Liver, Intestine, and Kidney Using Nanobore Liquid Chromatography-Tandem Mass Spectrometry
David E. Harbourt et al.
ANALYTICAL CHEMISTRY (2012)
Discovery and optimization of potent and selective imidazopyridine and imidazopyridazine mTOR inhibitors
Emily A. Peterson et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2012)
Targeting Stat3 Abrogates EGFR Inhibitor Resistance in Cancer
Malabika Sen et al.
CLINICAL CANCER RESEARCH (2012)
STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers
Xiaochun Wang et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2012)
STAT3 SIGNALING: Anticancer Strategies and Challenges
Paul A. Johnston et al.
MOLECULAR INTERVENTIONS (2011)
Probing the links between in vitro potency, ADMET and physicochemical parameters
M. Paul Gleeson et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
N-glucuronidation of drugs and other xenobiotics by human and animal UDP-glucuronosyltransferases
Sanna Kaivosaari et al.
XENOBIOTICA (2011)
Discovery of a novel sulfonamide-pyrazolopiperidine series as potent and efficacious γ-secretase inhibitors (Part II)
Xiaocong M. Ye et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2010)
Excretion and Metabolism of Lersivirine (5-{[ 3,5-Diethyl-1-(2-hydroxyethyl)(3,5-14C2)-1H-pyrazol-4-yl]oxy}benzene-1,3-dicarbonitrile), a Next- Generation Non-Nucleoside Reverse Transcriptase Inhibitor, after Administration of [14C]Lersivirine to Healthy Volunteers
Manoli Vourvahis et al.
DRUG METABOLISM AND DISPOSITION (2010)
Signal Transducer and Activator of Transcription-3, Inflammation, and Cancer How Intimate Is the Relationship?
Bharat B. Aggarwal et al.
NATURAL COMPOUNDS AND THEIR ROLE IN APOPTOTIC CELL SIGNALING PATHWAYS (2009)
Quantitative Analysis of UDP-Glucuronosyltransferase (UGT) 1A and UGT2B Expression Levels in Human Livers
Takeshi Izukawa et al.
DRUG METABOLISM AND DISPOSITION (2009)
Preparation and optimization of a series of 3-carboxamido-5-phenacylaminopyrazole bradykinin B1 receptor antagonists
Darren Dressen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
STAT3 as a central mediator of neoplastic cellular transformation
David A. Frank
CANCER LETTERS (2007)
N-glucuronidation of the platelet-derived growth factor receptor tyrosine kinase inhibitor 6,7-(dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)-(3-fluoro-phenyl)-amine by human UDP-glucuronosyltransferases
Z Yan et al.
DRUG METABOLISM AND DISPOSITION (2006)
Methods to evaluate biliary excretion of drugs in humans: An updated review
Giulia Ghibellini et al.
MOLECULAR PHARMACEUTICS (2006)
Prediction of drug metabolism and interactions on the basis of in vitro investigations
O Pelkonen et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2005)
Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis
GL Niu et al.
ONCOGENE (2002)
Share Paper
